Roberto Bordonaro

4.7k total citations
115 papers, 1.7k citations indexed

About

Roberto Bordonaro is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Roberto Bordonaro has authored 115 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Roberto Bordonaro's work include Colorectal Cancer Treatments and Studies (56 papers), Cancer Treatment and Pharmacology (33 papers) and Lung Cancer Treatments and Mutations (21 papers). Roberto Bordonaro is often cited by papers focused on Colorectal Cancer Treatments and Studies (56 papers), Cancer Treatment and Pharmacology (33 papers) and Lung Cancer Treatments and Mutations (21 papers). Roberto Bordonaro collaborates with scholars based in Italy, France and United Kingdom. Roberto Bordonaro's co-authors include Stefano Cordio, Michele Reni, Luca Falzone, Massimo Libra, Caterina Stelitano, Carlo Milandri, Evaristo Maiello, Gerardo Rosati, Paolo Passoni and Valerio Di Carlo and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Roberto Bordonaro

111 papers receiving 1.7k citations

Peers

Countries citing papers authored by Roberto Bordonaro

Since Specialization

Citations

This map shows the geographic impact of Roberto Bordonaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Bordonaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Bordonaro more than expected).

Fields of papers citing papers by Roberto Bordonaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Bordonaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Bordonaro. The network helps show where Roberto Bordonaro may publish in the future.

Co-authorship network of co-authors of Roberto Bordonaro

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Bordonaro. A scholar is included among the top collaborators of Roberto Bordonaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Bordonaro. Roberto Bordonaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Non-Colorectal Liver Metastases Undergoing Liver Resection: The NONCOLMET Study Group 2025 ·Digestive Surgery ·Marcello Di Martino, Giorgio Ercolani, Federica Cipriani, Gian Luca Baiocchi, Roberto Bordonaro, Matteo Cescon, Antonio Frena, (unknown), Gian Luca Grazi, Salvatore Gruttadauria, (unknown), (unknown), Fabrizio Panaro, Fabrizio Romano, Andrea Ruzzenente, Marcello Spampinato, Guido Alberto Massimo Tiberio, Guido Torzilli, Roberto Troisi, Matteo Donadon, (unknown)	0
2	6MO Evaluation of plasma assessed comprehensive genomic profiling before first-line treatment with FOLFIRI plus cetuximab in RAS/BRAFV600E wild type metastatic colorectal cancer patients in the CAPRI 2-GOIM trial 2024 ·Annals of Oncology ·(unknown), Erika Martinelli, Teresa Troiani, Stefania Napolitano, (unknown), (unknown), Salvatore Pisconti, Emiliano Tamburini, (unknown), Roberto Bordonaro, Claudio Lotesoriere, Sara Lonardi, Donatella Iacono, Belinda Borrelli, (unknown), Giampaolo Tortora, (unknown), (unknown), Fortunato Ciardiello, (unknown)	1
3	114P Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial 2024 ·ESMO Open ·(unknown), (unknown), (unknown), (unknown), Teresa Troiani, Evaristo Maiello, Antonio Avallone, Salvatore Pisconti, Roberto Bordonaro, Emiliano Tamburini, Claudio Lotesoriere, Maria Giulia Zampino, Nicola Fazio, Giuseppe Curigliano, Fortunato Ciardiello, Giulia Martini	2
4	422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018) 2022 ·Annals of Oncology ·Angela Damato, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Filippo Pietrantonio, Giuseppe Tonini, Evaristo Maiello, Roberto Bordonaro, (unknown), (unknown), Francesco Iachetta, (unknown), Giuseppe Maglietta, Nicola Normanno, Carmine Pinto	1
5	Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) 2021 ·Recenti Progressi in Medicina ·Claudio Jommi, Patrizio Armeni, Francesco Costa, (unknown), Francesco Bandello, Roberto Bordonaro, (unknown), Massimo Di Maïo, (unknown), Giovanni Giuliani, Roberto Langella, Anna Maria Marata, (unknown), Carmine Pinto, Guido Rasi, (unknown)	2
6	Italian Results of the PRECONNECT Study: Safety and Efficacy of Trifluridine/tipiracil in Metastatic Colorectal Cancer 2021 ·Future Oncology ·Alberto Zaniboni, Carlo Barone, Maria Banzi, Francesca Bergamo, Livio Blasi, Roberto Bordonaro, Maria Di Bartolomeo, Francesco Di Costanzo, Giovanni Luca Frassineti, Carlo Garufi, Francesco Giuliani, Tiziana Pia Latiano, Erika Martinelli, Nicola Personeni, Patrizia Racca, Emiliano Tamburini, Giuseppe Tonini, (unknown), (unknown), Alfredo Falcone	6
7	Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study 2021 ·ESMO Open ·Roberto Bordonaro, Aitana Calvo, A. Auriemma, Antoine Hollebecque, Gábor Rubovszky, Mark Saunders, Zsuzsanna Pápai, Gerald W. Prager, Alexander Stein, Thierry André, Guillem Argilés, Antonio Cubillo, Laëtitia Dahan, Julien Edeline, (unknown), Valérie Cattan, Ronan Fougeray, Nadia Amellal, Josep Tabernero	11
8	Out-of-pocket costs in gastrointestinal cancer patients: Lack of a perfectly framed problem contributing to financial toxicity 2021 ·Critical Reviews in Oncology/Hematology ·Roberto Bordonaro, Dario Piazza, (unknown), Stefano Cordio, (unknown), Vittorio Gebbia	4
9	Liability of clinical oncologists and the COVID-19 emergency: Between hopes and concerns 2020 ·Journal of Cancer Policy ·Vittorio Gebbia, Roberto Bordonaro, Livio Blasi, Dario Piazza, (unknown), Carmelo Iacono, Massimiliano Spada, Paolo Tralongo, Alberto Firenze	5
10	Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists 2020 ·ecancermedicalscience ·Livio Blasi, Roberto Bordonaro, Nicolò Borsellino, (unknown), Michele Caruso, Stefano Cordio, (unknown), Francesco Ferraù, Dario Giuffrida, Héctor Soto Parrà, Massimiliano Spada, Paolo Tralongo, Roberto Valenza, Francesco Verderame, S. Vitello, (unknown), Dario Piazza, Alberto Firenze, Vittorio Gebbia	10
11	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition 2019 ·Clinical Colorectal Cancer ·Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, Stefano Cordio, Sara Lonardi, (unknown), Alberto Zaniboni, Roberto Bordonaro, Maria Di Bartolomeo, Gianluca Tomasello, Vincenzo Dadduzio, Maria Chiara Tronconi, (unknown), Laura Giordano, Annunziata Gloghini, Luca Di Tommaso, Armando Santoro	42
12	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives 2016 ·Oncotarget ·V. Fanotto, Elena Ongaro, Karim Rihawi, Antonio Avallone, Nicola Silvestris, Lorenzo Fornaro, Enrico Vasile, Lorenzo Antonuzzo, Francesco Leone, Gerardo Rosati, Francesco Giuliani, Roberto Bordonaro, Mario Scartozzi, Giovanna De Maglio, Francesca Negri, Gianpiero Fasola, Giuseppe Aprile	26
13	Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial 2016 ·Annals of Oncology ·Evaristo Maiello, Erika Martinelli, Claudia Cardone, Teresa Troiani, Nicola Normanno, Salvatore Pisconti, Roberto Bordonaro, Francesco Giuliani, M. Biglietto, C. Barone, Anna Maria Rachiglio, Vincenzo Montesarchio, Giuseppe Tonini, Saverio Cinieri, Daniele Rizzi, Antonio Febbraro, Tiziana Latiano, (unknown), Giuseppe Colucci, Fortunato Ciardiello	4
14	Interim Analysis Results of Above Phase II Study with Bevacizumab in Patients with Initially not Resectable/Borderline Resectable Colorectal Liver-Limited Metastases 2013 ·Annals of Oncology ·Salvatore Artale, Guglielmo Nasti, Monica Ronzoni, Roberto Bordonaro, Maria Giulia Zampino, Silvia Brugnatelli, Andrea Sartore‐Bianchi, Azzurra Onofri, Angelo Vanzulli, Valentina Angelini, Salvatore Siena	1
15	Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 2013 ·Cancer Chemotherapy and Pharmacology ·Marcello Tiseo, Massimo Ippolito, (unknown), P. Spadaro, Sebastiano Cosentino, (unknown), Livia Ruffini, Marco Bartolotti, Beatrice Bortesi, Claudia Fumarola, Cristina Caffarra, Andrea Cavazzoni, Roberta Alfieri, Pier Giorgio Petronini, Roberto Bordonaro, Paolo Bruzzi, Andrea Ardizzoni, Héctor Soto Parrà	27
16	Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study 2011 ·Investigational New Drugs ·Gerardo Rosati, Stefano Cordio, Giuseppe Aprile, (unknown), Antonio Avallone, Giuseppe Di Lucca, (unknown), Héctor Soto Parrà, Giorgio Reggiardo, Roberto Bordonaro	7
17	A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer 2007 ·Anti-Cancer Drugs ·(unknown), Alessandro Pappalardo, Antonio Russo, Daniele Santini, (unknown), (unknown), Sergio Castorina, (unknown), (unknown), (unknown), (unknown), Roberto Bordonaro	8
18	Feasibility of Sequential Therapy with FOLFIRI Followed by Docetaxel/Cisplatin in Patients with Radically Resected Gastric Adenocarcinoma 2006 ·Oncology ·Maria Di Bartolomeo, Roberto Buzzoni, Luigi Mariani, Erminia Ferrario, Katia Dotti, Arpine Gevorgyan, Nicoletta Zilembo, Roberto Bordonaro, Anna Maria Bochicchio, B. Massidda, Antonio Ardizzoia, Giovanni Marini, Enrico Aitini, (unknown), Giuseppe Comella, (unknown), Salvatore Palazzo, (unknown), Emilio Bajetta	11
19	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas 2005 ·Annals of Oncology ·S. Monfardini, Savina Aversa, Valerio Zoli, Luigi Salvagno, (unknown), Roberto Bordonaro, Giulia Benevolo, Monica Crugnola, Gino Crivellari, (unknown), Umberto Basso, Valter Torri	29
20	Phase II Trial of Oxaliplatin and Tegafur/Uracil and Oral Folinic Acid for Advanced or Metastatic Colorectal Cancer in Elderly Patients 2005 ·Oncology ·Gerardo Rosati, Stefano Cordio, (unknown), (unknown), Roberto Bordonaro, Giorgio Reggiardo, Luigi Manzione	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact